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Background: Surgical resection of colorectal liver metastases (CRLMs) is the standard of care when 
possible, although this strategy has not been compared with non-operative interventions in controlled 
trials. Although survival outcomes are clear, the cost-effectiveness of surgery is not. This study aimed 
to estimate the cost-effectiveness of resection for CRLMs compared with non-operative treatment 
(palliative care including chemotherapy). 
Methods: Operative and non-operative cohorts were identified from a prospectively maintained 
database. Patients in the operative cohort had a minimum of 10 years of follow-up. A model-based 
cost–utility analysis was conducted to quantify the mean cost and quality-adjusted life-years (QALYs) 
over a lifetime time horizon. The analysis was conducted from a healthcare provider perspective (UK 
National Health Service) in a secondary care (hospital) setting. 
Results: Median survival was 41 and 21 months in the operative and non-operative cohorts 
respectively (P < 0.001). The operative strategy dominated non-operative treatments, being less costly 
(€22 200 versus €32 800) and more effective (4.017 versus 1.111 QALYs gained). The results of 
extensive sensitivity analysis showed that the operative strategy dominated non-operative treatment in 
every scenario. 
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Conclusion: Operative treatment of CRLMs yields greater survival than non-operative treatment, and 
is both more effective and less costly.  
 
+A: Introduction 
Colorectal cancer is one of the commonest malignant diseases worldwide
1
 and 30–40 per cent of 
patients develop colorectal liver metastases (CRLMs)
2,3
. Without treatment the median survival 
amongst historical patient cohorts with CRLMs suitable for resection was 6–12 months4,5; the use of 
novel chemotherapeutics can extend median survival to 21 months
6
. When possible, resection of 
CRLMs is associated with a 5-year survival rate of 27–39 per cent7–10, although with patient cohorts 
having follow-up for 10 years it is now clear that 5-year survival does not define cure following 
CRLM resection. Between 11 and 23 per cent of 5-year survivors subsequently develop recurrent 
metastatic disease, and episodes of recurrence reach a plateau by 10 years
11–13
. Thus 10 years of 
follow-up are required to identify all disease-specific outcomes following the initial treatment of 
CRLMs. 
The development of surgical resection as a widely adopted treatment for CRLMs was a 
paradigm change in the management of metastatic disease, and is one of the most exciting advances in 
surgical practice in recent times. However, in an era of financial austerity and expanding healthcare 
costs, the financial burden of treating patients with CRLMs is not known. There are barriers to 
understanding the cost-effectiveness of surgical resection of CRLMs compared with alternative 
therapies: there is no randomized clinical trial available; an extensive period of follow-up is required 
to identify all cancer-related outcomes in the surgery group and, therefore, costs; a comparator non-
operative group selected from non-randomized cohorts is likely to be disadvantaged owing to 
selection bias (having more patients with widespread metastatic disease or those unfit for surgery); 
and novel chemotherapeutic agents continue to be developed which increase survival but are likely to 
be associated with increasing costs
14–17
.  
This study used observational data from two separate patient cohorts to undertake a model-
based economic evaluation that examined the cost-effectiveness of surgery compared with non-
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operative treatment for patients with CRLMs. The results are presented in terms of cost per additional 
quality-adjusted life-year (QALY) gained. 
+A: Methods 
The data used in this cost–utility analysis were from an observational study of two patient cohorts. 
The operative cohort consisted of patients with a minimum of 10 years’ potential follow-up in order to 
capture all episodes of disease recurrence and outcomes. The non-operative cohort was selected 
carefully to control for selection bias in a number of ways. First, as chemotherapy regimens have 
evolved to include oxaliplatin and irinotecan
18,19
 and, more recently, monoclonal antibodies
20–22
, a 
contemporary patient cohort was used as the comparison group to reflect the improvement in median 
survival associated with these treatments. Second, to avoid including patients with a prognosis 
adversely affected by metastatic disease burden or co-morbidity, only those considered fit enough for 
liver surgery and with liver-only metastatic disease were included in the non-operative cohort. The 
decision that these patients could not safely undergo surgery was made at a dedicated liver surgery 
multidisciplinary team meeting. Disease was considered unresectable when: resection of all CRLMs 
would not leave an adequate volume of future liver remnant; and resection was not technically 
possible, owing to tumours located at the portal bifurcation or the confluence of the hepatic veins.  
The operative cohort comprised consecutive patients undergoing CRLM resection between 28 
December 1992 and 24 September 2001, and entered into a prospectively maintained institutional 
database at St James’s University Hospital, Leeds, UK. The outcome of this cohort has been described 
in detail previously when comparing the ability of scoring systems to predict long-term oncological 
outcomes
23
. The start of the study coincided with the inception of the liver resection programme at 
this institution, and the end date permitted a minimum of 10 years actual follow-up for each patient. 
To provide an accurate assessment of the cost and outcome of treating patients with CRLMs, all 
patients were included in the present study, including those who died after surgery; such postoperative 
deaths were excluded in previous reports of 10-year follow-up after surgical resection of CRLM
11,24
.  
Following liver resection all patients received intensive surveillance consisting of CT of the 
thorax, abdomen and pelvis at 3, 6, 12, 18 and 24 months, then in years 3, 4, 5, 7 and 10. In  addition, 
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a clinical review with tumour marker measurement (carcinoembryonic antigen, CEA), routine 
haematology and biochemical analysis was carried out at 3, 6, 12, 18 and 24 months, then annually 
until the tenth year of follow-up; there was no further review after this. As a result of this intensive 
surveillance, all episodes of disease recurrence together with outcomes and treatments were recorded. 
If a patient underwent resection of hepatic or extrahepatic recurrent disease, surveillance was restarted 
at the beginning of the protocol. Survival data including causes of death were obtained from hospital 
records, by discussion with individual patients’ general practitioners, and by cross-referencing these 
data with those held by the Northern and Yorkshire Cancer Registry Information Service. 
The non-operative cohort was identified from a review of patients who were presented to a 
dedicated liver surgery multidisciplinary team between January 2008 and January 2010, as described 
above. For each patient the various chemotherapy regimens and number of cycles administered were 
recorded. The outcome and costs associated with treating this cohort were directly compared with 
those in the surgery group. The number of episodes of palliative chemotherapy and survival time from 
multidisciplinary team review until death were calculated for each patient. 
+B: Cost and resource use data 
For each subject, costs of investigation, follow-up and treatment were calculated based on Healthcare 
Resource Groups (HRGs). HRG4 is the current standard in the UK used by the National Health 
Service (NHS). HRGs are adjusted to reflect case mix, and are based on direct, indirect and overhead 
costs associated with each reference cost that is measured. Each HRG code considers an individual’s 
age, sex, co-morbidity, primary and secondary diagnoses (using the World Health Organization ICD-
10 classification) and primary procedure codes (OPCS version 4.6). The incidence and nature of 
postoperative complication(s) were also taken into account. 
The following costs were calculated.  For the operative cohort, the costs of index liver 
resection and any further resection of hepatic or extrahepatic recurrent disease (including 
radiofrequency ablation) were considered. Costs of follow-up as described above were also 
incorporated, which included costs associated with outpatient clinical review, blood tests (full blood 
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count, routine biochemistry and CEA analysis) and surveillance imaging (CT of 3 body regions with 
contrast; MRI [when performed to review indeterminate lesions] of 1 body region); and palliative 
treatment including chemotherapy informed by outcomes of the regimens used in the non-operative 
cohort.  
For the non-operative cohort, the costs of each chemotherapy regimen and the number of 
cycles provided, along with the number of follow-up appointments and CT or MRI scans, were 
recorded for each patient. 
Cost analysis was based on NHS reference costs for healthcare provided in the 2010–2011 
financial year
25
 and converted from pounds sterling to euros (€1.26 = £1; exchange rate 21 November 
2014). The resource use data for the analysis were based on the experience of the patients in the two 
cohorts (Table 1). The Mann–Whitney U test was used for analysis of continuous data and Fisher’s 
exact test for categorical data. Survival analysis was done using the Kaplan–Meier method. All 
analyses were performed using SPSS version 19 (IBM, Armonk, New York, USA), and P < 0.050 
was considered statistically significant. 
+B: Economic model 
+C: Model structure 
The model used in this study was developed through consultation with the clinical team using key 
clinical and modelling expertise. A Markov model was implemented in TreeAge Pro 2001 software 
(TreeAge Software, Williamstown, Massachusetts, USA). This approach was deemed to be most 
appropriate owing to the chronic nature of colorectal cancer and there being examples of the same 
event occurring multiple times over the time horizon of the study (such as a patient experiencing 
cancer recurrence many years into the future). Because of the reduced length of survival for this 
patient group, and the possibility of relevant events occurring for the remainder of their lives, a 
lifetime time horizon for the model was adopted. A weekly time cycle was used in order to capture the 
increased costs of an inpatient stay after surgery,  
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For the operative arm, all patients in the model initially undergo surgical resection, and are 
then followed over time. These patients may suffer a cancer-related death, cancer recurrence or die 
from natural causes at some stage in the future. For those with cancer recurrence, the immediate 
response will be either to undertake another surgical resection (hepatic or extrahepatic), or they may 
be judged to be inoperable, in which case they may or may not go on to receive chemotherapy for the 
remainder of their lives. The Markov model for the operative pathway is shown Fig. S1 (supporting 
information). Patients in the non-operative arm in the model either receive chemotherapy or not, and 
remain in these states for the remainder of their lives.  
+C: Assumptions and parameterization 
The majority of the model parameters and transition probabilities between the states were calculated 
from the data set and are described in Tables S1 and S2 (supporting information). A number of 
assumptions were necessary to implement a workable model structure. These are described here and 
in the tables of parameters where appropriate. First, patients in the operative arm who develop a 
recurrence, and are then deemed inoperable, will become similar to patients in the non-operative arm 
and thus will incur the same costs after recurrence and experience the same rate of survival as those 
patients. Second, all chemotherapy costs are evenly distributed throughout the remainder of the 
patients’ lives. Third, costs of palliative treatment among patients in the operative arm who develop 
recurrent unresectable disease are based on the cost of treating patients in the contemporary non-
operative group and not of the actual treatment received. This is because, given the duration of 
follow-up in the surgical group, almost all palliative chemotherapy was in the form of 5-fluorouracil 
compounds, and these are cheaper than drugs available to patients within the contemporary cohort. 
Fourth, the mortality rate and length of stay for resection of extrahepatic procedures is the same as 
that for hepatic disease. Finally, the age of the patients in both cohorts is 62 years; this assumption 
was made to avoid bias against the non-operative cohort (median age 65 years). The impact of the 
ages of the cohorts on the model results was examined during the one-way sensitivity analysis. 
+C: Analysis 
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This economic evaluation used the QALY as the primary outcome measure, which is the preferred 
measure as recommended by the National Institute for Health and Care Excellence (NICE)
27
. The 
QALY considers the quality of life (QoL) of patients over time; 1 QALY represents 1 year of perfect 
health.  
No QoL data were available from the complete observational data set, and so it was necessary 
to parameterize this model with QoL data from secondary data sources. Each of the model states in 
the Markov model were allocated a QoL value, with patients who are inoperable with and without 
chemotherapy taking the same QoL values in both the operable and inoperative arms. A proportion of 
the extrahepatic procedures were video-assisted thoracoscopic procedures and this proportion was 
factored into the QoL values for patients in this state. The QoL values used in this analysis are 
described in Table  S3 (supporting information). 
At baseline the model estimated the mean costs and effectiveness for each of the treatment 
strategies. Discounting was applied at 3.5 per cent for costs and outcomes as recommended by HM 
Treasury
31
. The analysis was conducted from a healthcare provider perspective (UK NHS) as 
recommended by NICE
27
 in a secondary care (hospital) setting. As costs could be incurred throughout 
the lifetime of the patients, half-cycle correction was applied to both costs and outcomes.  
+C: Sensitivity analysis 
Probabilistic sensitivity analysis was carried out to examine the impact of uncertainties in the model 
parameters on the robustness of the model results. Beta distributions were used for all transition 
probabilities and utility values, with costs being described by normal distributions with their standard 
error values obtained from bootstrapping (Table S4, supporting information).  
One-way sensitivity analysis was carried out to provide further insight into the impact of 
specific parameters on the model results. This examined the impact of varying the assumed age of the 
patient cohort, varying the time horizon, and removing discounting from the model.  
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One of the key assumptions in this analysis was that the non-operative cohort in this data set 
can be reasonably used to represent a group of patients who are offered chemotherapy instead of 
resection. However, because these patients are inoperable it is likely that their mean colorectal cancer-
related death rate will be greater than that for all patients with colorectal cancer. To investigate the 
impact of this factor on the results of the model, in the one-way sensitivity analysis the colorectal 
cancer-related death rate for the chemotherapy strategy for those that do or do not receive 
chemotherapy was reduced by half. By varying the death rate in this way the impact of the improved 
efficacy of future chemotherapy agents could also be examined. 
+A: Results  
The median (i.q.r.) survival of the 286 patients in the operative cohort was 41 (17–97) months over a 
potential median follow-up of 151 months. At final follow-up, 18 patients (6.3 per cent) had died 
within 90 days or during the hospital admission, 58 (20.3 per cent) were alive and disease-free, 192 
(67.1 per cent) had died from the disease, 14 (4.9 per cent) from an unrelated cause, and four (1.3 per 
cent) were lost to follow-up or had died from an unknown cause. Seventy patients (24.5 per cent) had 
undergone a total of 105 further hepatic or extrahepatic resections for recurrent disease. Further 
details of the two cohorts are reported in Table 1. 
Among the non-operative cohort of 46 patients, median (i.q.r.) survival was 21 (10–29) 
months over a potential median follow-up of 57 (55–62) months. One patient (2 per cent) was alive 
with disease 34 months after diagnosis of CRLM; the remaining patients all died from disease. The 
overall survival rate at 1, 3, 5 and 10 years was 80.9, 54.2, 36.1 and 21.9 per cent respectively in the 
operative cohort, and 70, 13, 0–2 and 0–2 per cent respectively in the non-operative cohort (the 
variation at 5 and 10 years in latter group was due to the single survivor) (Fig. 1). 
In the non-operative cohort the reasons for inoperability were CRLMs at the bifurcation of the 
portal vein/hilum (14) or inferior vena cava/hepatic vein confluence (8), or a pattern of disease that 
could not be resected to safely leave an adequate future liver remnant (29). Some patients had more 
than one reason. 
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Twelve patients in the non-operative cohort either declined or were not offered palliative 
chemotherapy. Among the remaining patients, 54 cycles of capecitabine, 55 of intravenous 5-
fluoruracil, 144 of oxaliplatin, 96 of irinotecan, 52 of cetuximab, and eight of bevacizumab or 
panitumumab were administered. Various combinations of these drugs were given; the cost analysis 
was based on the actual regimen received by each patient and the NHS tariff associated with that 
regimen and route of delivery (Table 2). 
+B: Cost-effectiveness of treatments 
Taking the parameters at their baseline values, the operative strategy was both cheaper and more 
effective than the non-operative strategy (Table 3). 
+C: Sensitivity analysis 
The results of the probabilistic sensitivity analysis are shown in the cost-effectiveness plane (Fig. 2). 
This indicates that in the majority of patients the operative strategy is both more effective and less 
costly than the non-operative strategy (majority of points in the south-east quadrant of the cost-
effectiveness plane). A number of points lie in the north-east quadrant indicating that the operative 
strategy is more expensive and more effective than non-operative treatment; the few points in the 
south-western quadrant indicate the possibility that surgery may be less costly and less effective than 
non-operative treatment. It is interesting to note that, when allowing for the uncertainty in model 
parameters, the operative strategy was never found to be more expensive and less effective than the 
non-operative strategy.  
Fig. 3 shows the cost-effectiveness acceptability frontier generated from the results of the 
probabilistic sensitivity analysis. This indicates that the operative approach is always likely to be the 
optimal strategy across all willingness-to-pay values for a QALY, and is certain to be the preferred 
strategy at willingness-to-pay values for a QALY of €6000 or greater. 
+C: One-way sensitivity analysis 
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The results of various one-way sensitivity analyses show that varying the assumed age of the cohorts, 
the time horizon, and removing discounting from the model all have very little impact on the results 
or conclusions drawn from the model (Table 3). Excluding the 18 postoperative deaths, the median 
(i.q.r.) survival in the operative cohort increased to 43 (20–111) months, and excluding the 12 patients 
who received no chemotherapy increased median survival in the non-operative cohort to 24 (14–33) 
months. The effects of these exclusions in isolation have very little impact on the results or 
conclusions drawn from the model, and in combination the conclusions from the model remain 
unchanged. Interestingly, reducing the death rates for the non-operative pathway by half increases the 
QALY gain for this strategy, but this is still far below that of the operative pathway. 
Two models were included to disadvantage the operative cohort and render this more 
comparable to the palliative nature of the non-operative cohort. The first was to exclude all survivors 
from the surgical cohort and thus include only patients who ultimately had a cancer-related death. The 
second was to include only patients with involved surgical margins or those with tumours within 1 
mm (R1 resection). Both scenarios remain less costly and yielded greater QALYs than non-operative 
treatment. 
+A: Discussion 
This study describes data from an observational study of two patient cohorts, which was then applied 
to a full economic model to estimate the cost-effectiveness of operative management of CRLMs 
compared with non-operative management. In analyses of overall survival in non-randomized 
prospective cohorts, the superiority of liver resection over non-operative treatment in patients with 
resectable disease was overwhelming
11–13,18–22
. The present study demonstrates that surgical treatment 
of CRLMs yields a much greater duration of survival together with a chance of cure, despite being 
associated with a lower cost than palliative treatment based on chemotherapy. The results from the 
economic evaluation indicate that, using the QALY as outcome measure, the strategy in which all 
patients with CRLMs undergo surgery is both less costly and more effective than offering all patients 
non-operative treatments in the form of chemotherapy. 
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The conclusions drawn from the present economic analysis were also found to be robust to 
changes to key parameters in the model. The age of the cohort, the time horizon of the analysis, and 
even changes to the death rate of patients in the non-operative arm had no effect on the conclusions 
drawn. The operative strategy continued to be both less costly and more effective than non-operative 
treatment. Moreover, exclusion of postoperative deaths and patients who received no chemotherapy in 
the non-operative cohort also had very little impact on the results or conclusions. The operative 
strategy remained dominant compared with non-operative treatment when it was adjusted to become 
essentially a palliative procedure, that is when only those patients with an involved surgical margin 
(R1) were included or even when all 10-year survivors were excluded from the analysis. 
Furthermore, varying all the parameters in probabilistic sensitivity analysis showed that 
operative management is certainly the preferred strategy for willingness-to-pay values per QALY of 
€6300 and above, which is well below the NICE acceptance threshold of €25 200–37 80032. 
The present study has several limitations. The time over which the cohort undergoing surgical 
resection was observed to accurately identify all relevant outcomes, and thus enable accurate cost 
efficacy, spans an interval during which chemotherapy regimens evolved considerably in terms of 
efficacy and costs. Thus an attempt was made to identify all pertinent outcomes and 
treatment/surveillance interventions in both cohorts to provide an accurate cost-effectiveness 
assessment. Had the non-operative cohort been selected at the same time as the operative cohort 
underwent initial liver resection, the chemotherapy drugs and outcomes would not be relevant to 
contemporary treatment. It could be argued that by excluding contemporary patients undergoing 
operative treatment the costs associated with laparoscopic liver resection have been neglected and so a 
more contemporary cohort is required to assess cost-effectiveness. However, it seems unlikely that 
this strategy would affect survival time and so the costs of alternative surgical treatments can be 
investigated easily within such a Markov model. The same applies to robotic surgery, if it is assumed 
that disease-free and disease-specific survival are not affected.  
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The operative cohort represents a large number of consecutive patients without exclusion; 
only 1.4 per cent were lost to follow-up or had an uncertain cause of death. Furthermore, the 
minimum of 10 years’ potential follow-up adds confidence to the conclusions drawn from the 
economic model. However, to compare the efficacy of this treatment, the non-operative cohort was 
selected carefully to allow comparison of outcomes of the two treatments in a similar group of 
patients. The two most common reasons why patients with metastatic colorectal cancer do not 
undergo liver resection of CRLMs are widespread extrahepatic metastases and advanced age/co-
morbidity. These patients were excluded from the non-operative cohort in an attempt to avoid 
disadvantaging this group. Only patients with liver-only metastatic disease and in whom liver surgery 
would be considered were included in the non-operative cohort. This group is still likely to be 
disadvantaged compared with the operative cohort given that the burden of hepatic disease precluded 
resection. However, in other respects the operative group was potentially disadvantaged as patients 
with extrahepatic disease at the time of liver resection were not excluded from the present study. 
Without a randomized trial, studies comparing operative and non-operative treatments will always be 
open to selection bias/confounding. The model parameters were adjusted to benefit the non-operative 
cohort by excluding patients who did not receive chemotherapy and by assuming improved efficacy 
of future chemotherapeutic agents. An analysis was also done with exclusion of all survivors in the 
operative cohort to give essentially a palliative group of operated patients, but the outcome remained 
the same with operative treatment being more cost-effective in every scenario.  
A further assumption in this analysis was that chemotherapy costs are distributed evenly over 
a patient’s lifetime. In reality it is likely that these patients will stop receiving chemotherapy towards 
the end of their lives. In terms of the present analysis, this means that the costs in the non-operative 
arm may be higher than estimated here, as discounting will have less of an impact if the costs are 
incurred sooner. This helps increase confidence in the conclusion that offering resection to all patients 
with colorectal cancer is both less costly and more effective than offering chemotherapy instead. 
One conclusion of this work is that the standard of care should be liver resection in patients 
who are fit for surgery, and have resectable hepatic metastases and no extrahepatic disease. This is 
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based on improved survival, QoL and cost-effectiveness analysis. It can be concluded from the results 
here that strategies to identify early disease recurrence and increase the proportion of patients 
undergoing liver resection may make financial sense if the costs of identifying these patients are not 
prohibitive. Presently there is worldwide concern that some patients with resectable CRLMs are not 
referred for specialist review
33
. Furthermore, strategies to increase the proportion of patients with 
CRLMs who can undergo resection, such as two-stage liver resections
34
, portal vein embolization
35
 
and downstaging chemotherapy
26
, should be supported as they are likely to be financially worthwhile 
endeavours. This study has clearly put into a financial context the position of surgery against other 
treatments. This information is particularly useful for financially constrained healthcare systems to 
inform where funding may be most usefully allocated. 
The QoL estimates in this analysis were taken from a number of secondary sources, some of 
which are a number of years old. As treatment practices improve, it is likely that these will have less 
of an impact on patients’ QoL, and also help to prolong their survival. Recovery from operative 
procedures may be improving, and the side-effects from new chemotherapy drugs may be less severe 
than those of agents used in the past.  
Other potentially curative treatments for CRLMs include ablation therapies (percutaneous or 
intraoperative) and minimally invasive techniques, although these were not reviewed for the present 
study. These treatments could also improve QoL outcomes
28
. Given that there is no evidence to 
suggest that the recurrence rate after ablation
29
 or laparoscopic surgery
30
 is higher than that after open 
surgery, these strategies could further improve the delivery of curative treatments in selected patients.  
Chemotherapy is now being used to improve oncological outcomes after CRLM resection
36
 
and increasingly to bring initially unresectable disease to a state where liver resection is possible
37
. 
These issues further complicate any future cost-effectiveness analyses, and demonstrate the close 
relationship between surgeons, oncologists and their patients. Therefore, future research could 
investigate the impact of current practice on QoL, and the present analysis could then be updated 
based on this new information. 
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Fig. S2 Scatter plots and cost-effectiveness acceptability curves for the probabilistic sensitivity analysis, 
assuming that: a,b there are no postoperative deaths following initial resection in the operative pathway; c,d 
all patients in the non-operative pathway receive chemotherapy; e,f there are no postoperative deaths 
following initial resection in the operative pathway and all patients in the non-operative pathway receive 
chemotherapy; and g,h all patients in the operative pathway have involved surgical margins (Word 
document) 
Fig. S3 Scatter plot and cost-effectiveness acceptability curve for the probabilistic sensitivity analysis 
assuming that there were no survivors at 10 years in the operative pathway (Word document) 
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Fig. 1  Survival curves for operative and non-operative cohorts. Only patients who had non-cancer 
non-postoperative deaths were censored in the operative cohort. One patient who was alive was 
censored in the non-operative cohort. Median survival was 21 (i.q.r. 10–29) and 41 (17–97) months 
for the non-operative and operative cohorts respectively (P < 0.001, Cox regression analysis). The 
effects of including only those who received chemotherapy in the non-operative cohort, and excluding 
all early postoperative deaths in the operative cohort, are also shown  
Fig. 2 Scatter plot showing the results of probabilistic sensitivity analysis for baseline parameters. 
QALY, quality-adjusted life-year  
Fig. 3 Cost-effectiveness acceptability frontier across a range of willingness-to-pay thresholds for a 
quality-adjusted life-year (QALY) 
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Table 1 Summary of the cohort undergoing operative and non-operative treatment for colorectal liver 
metastases, including pathological features of colorectal and hepatic tumours, hepatic surgery and 
outcomes 
 
Operative cohort 
(n = 286) 
Non-operative cohort  
 (n = 46) 
 
P§ 
Age (years)* 62 (54–69) 65 (56–74) 0.186¶ 
Sex ratio (M : F) 170 : 116 28 : 18 0.920 
Synchronous CRLMs 132 (46.2) 19 (41) 0.680 
Extrahepatic disease at time of diagnosis of 
CRLMs 
27 (9.4) 0 (0) 0.061 
Adjuvant chemotherapy of CRC 86 (30.1) 30 (65.2) < 0.001 
N1 primary CRC 157 (54.9) 31 (67.4) 0.140 
T4 primary CRC 90 (31.5) 8 (17.4) 0.081 
Interval between CRC and CRLM operations 
(days)* 
290 (132–651) 405 (130–885) 0.627¶ 
Bilobar disease 127 (44.4) 32 (70) 0.002 
No. of CRLMs*† 2 (1–4) 4 (3–6) < 0.001¶ 
Size of largest CRLM (cm)* 4 (2.6–6) 4 (3–5.3) 0.574¶ 
Complications  81 (28.3) –  
Further resection for CRC metastases 70 (24.5) –  
Follow up (months)* 151 (133–179) 57 (55–62) < 0.001¶ 
Survival (months)* 41 (17–97) 21 (10–29) < 0.001¶ 
Follow-up appointments* 6 (3–13) 26 (10–36) < 0.001¶ 
Follow-up CT (no. of scans)* 10 (5–19) 4 (2–6) < 0.001¶ 
Follow-up MRI (no. of scans)* 6 (3–13) 1 (0–1) < 0.001¶ 
Outcomes at final follow-up    
    Alive, disease-free 58 (20.3) 0 (0) 0.002 
    Alive, with disease 0 (0) 1 (2) 0.292 
    Died from disease 192 (67.1) 45 (98) < 0.001 
    Died in early postop. phase 18 (6.3) –  
    Died from an unrelated cause 14 (4.9) 0 (0) 0.258 
    Died from an unknown cause 3 (1.0) 0 (0) 0.887 
    Lost to follow-up 1 (0.3) 0 (0) 0.292 
Crude survival  
   1 year 
   3 years 
   5 years 
   10 years‡ 
 
80.9 
54.2 
36.1 
21.9 
 
70 
13 
0–2 
0–2 
 
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). 
†Number of lesions in the surgical resection specimen or identified at staging imaging in the non-
operative cohort. ‡Median follow-up for non-operative cohort does not exceed 5 years. CRLM, 
colorectal liver metastasis; CRC, colorectal cancer; N1, node-positive; T4, tumour breaches serosal 
wall. §Fisher’s exact test, except ¶Mann–Whitney U test.  
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Table 2 Resource use costs applied to economic evaluation 
 Code* Cost (€) Reference for cost notes 
Resection procedure 
 
 
GA03A, 
GA03B, 
GA04A, 
GA04B, 
GA05A, 
GA05B 
€7132.1 (93.7) 
 
 
 
NHS reference 
costs 
Bootstrapped from 
observational data to 
obtain mean and s.e. 
1-week postop. hospital 
stay  
 2886.6 (25.1) 
 
 Mean length of stay 
11.4 days 
Extrahepatic operation  
   Procedure 
   One-week hospital stay 
 
 
DZ02C  
5278 
3501 
NHS reference 
costs 
Bootstrapped from 
observational data to 
obtain mean and s.e. 
Mean length ofstay 
assumed to be same 
as for resection 
Chemotherapy 
 
SB01Z-SB17Z, 
SB97Z 
Mean weekly cost 
€429 (64.8) 
NHS reference 
costs 
Bootstrapped from 
observational data to 
obtain mean and s.e. 
Includes day-case and 
regular day/night 
appointments and 
outpatient visits. It is 
assumed that the 
chemotherapy costs 
are distributed evenly 
over time 
Outpatient appointments 315 260 NHS reference 
costs 
Assume four 
appointments in the 
first year postop. and 
one per year 
afterwards 
CT  RA13Z 204 NHS reference 
costs 
Two scans in the first 
year postop.; one per 
year subsequently 
MRI  RA05Z 461 NHS reference 
costs 
 
Inoperable patients   92.7 (weekly cost)  0.3 appointments per 
week, 0.0467 CT 
scans per week, 
0.0115 MRI scans  
per week, based on 
observational data 
Values in parentheses are s.e. *National Health Service (NHS) reference costs. 
  
 23 
 
Table 3 Results of one-way sensitivity analysis  
Strategy Cost (€) 
Effectiveness 
(QALYs 
gained) Cost-effectiveness 
Baseline    
   Non-operative 32 800  1.111  
   Operative 22 200 4.017 Dominates 
Assume all patients are aged 45 years 
   Non-operative 33 300 1.125  
   Operative 23 000 4.249 Dominates 
Assume all patients are aged 75 years 
   Non-operative 31 100 1.055  
   Operative 20 300 3.392 Dominates 
Time horizon limited to 10 years 
   Non-operative 32 700 1.106  
   Operative 20 600 3.533 Dominates 
No discounting     
   Non-operative 35 100 1.183  
   Operative 24 400 4.793 Dominates 
Reduce non-operative pathway death rates by half 
   Non-operative 60 400 2.052  
   Operative 22 200 4.017 Dominates 
Assume no postoperative deaths following initial resection in the operative pathway*  
   Non-operative 32 900 1.111  
   Operative 22 800 4.208 Dominates 
Assume all patients in non-operative pathway receive chemotherapy* 
   Non-operative 42 800 1.289  
   Operative 22 200 4.017 Dominates 
Assume no post-operative deaths following initial resection in operative pathway and all patients in non-
operative pathway receive chemotherapy* 
   Non-operative 42 800 1.289  
   Operative 22 800 4.208 Dominates 
Assume no survivors in operative pathway; all 10-year survivors excluded from analyses† 
   Non-operative 32 900 1.111  
   Operative 14 200 3.563 Dominates 
Assume all patients have involved surgical margins; all patients with R0 resection margins excluded from 
analyses* 
   Non-operative 32 900 1.111  
   Operative 22 900 2.802 Dominates 
*Results of probabilistic sensitivity analyses can be found in *Fig. S2 and †Fig. S3 (supporting 
information). QALY, quality-adjusted life-year.  
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